Treatment concepts in oncology are becoming increasingly personalized and diverse. Successively, changes in standards of care mandate continuous monitoring of patient pathways and clinical outcomes based on large, representative real-world data. The German Cancer Consortium’s (DKTK) Clinical Communication Platform (CCP) provides such opportunity. Connecting fourteen university hospital-based cancer centers, the CCP relies on a federated IT-infrastructure sourcing data from facility-based cancer registry units and biobanks. Federated analyses resulted in a cohort of 600,915 patients, out of which 232,991 were incident since 2013 and for which a comprehensive documentation is available. Next to demographic data (i.e., age at diagnosis: 2.0% 0–20 years, 8.3% 21–40 years, 30.9% 41–60 years, 50.1% 61–80 years, 8.8% 81+ years; and gender: 45.2% female, 54.7% male, 0.1% other) and diagnoses (five most frequent tumor origins: 22,523 prostate, 18,409 breast, 15,575 lung, 13,964 skin/malignant melanoma, 9005 brain), the cohort dataset contains information about therapeutic interventions and response assessments and is connected to 287,883 liquid and tissue biosamples. Focusing on diagnoses and therapy-sequences, showcase analyses of diagnosis-specific sub-cohorts (pancreas, larynx, kidney, thyroid gland) demonstrate the analytical opportunities offered by the cohort’s data. Due to its data granularity and size, the cohort is a potential catalyst for translational cancer research. It provides rapid access to comprehensive patient groups and may improve the understanding of the clinical course of various (even rare) malignancies. Therefore, the cohort may serve as a decisions-making tool for clinical trial design and contributes to the evaluation of scientific findings under real-world conditions.

肿瘤学的治疗理念正变得越来越个性化和多样化。随后，护理标准的变化要求根据大量具有代表性的真实世界数据持续监测患者路径和临床结果。德国癌症协会 (DKTK) 的临床交流平台 (CCP) 提供了这样的机会。CCP 连接 14 个大学医院的癌症中心，依靠联合 IT 基础设施从基于设施的癌症登记单位和生物库中采购数据。联合分析得出了一个包含 600,915 名患者的队列，其中 232,991 名患者是 2013 年以来发生的事件，并且有全面的文件可供使用。其次是人口统计数据（即诊断年龄：2.0% 0-20 岁，8.3% 21-40 岁，30.9% 41-60 岁，50.1% 61-80 岁，8.8% 81+ 岁；性别：45.2%女性，54.7% 男性，0.1% 其他）和诊断（五个最常见的肿瘤来源：22,523 例前列腺癌、18,409 例乳腺癌、15,575 例肺癌、13,964 例皮肤/恶性黑色素瘤、9005 例大脑），队列数据集包含有关治疗干预和反应评估的信息，并且已连接到 287,883 份液体和组织生物样本。专注于诊断和治疗顺序，展示特定诊断子队列（胰腺、喉、肾、甲状腺）的分析展示队列数据提供的分析机会。由于其数据粒度和规模，该队列是转化癌症研究的潜在催化剂。它提供了对综合患者群体的快速访问，并可能提高对各种（甚至罕见的）恶性肿瘤临床过程的理解。所以，